Celitec

Celitech is a clinical-stage biotechnology company focused on developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematologic malignancies and solid tumors. The company utilizes its proprietary Celi-CAR platform to engineer T-cells with enhanced persistence and anti-tumor activity, aiming to overcome the limitations of current cell therapies. Its lead programs target well-validated antigens such as CD19 and BCMA, with clinical trials underway for various B-cell lymphomas and multiple myeloma. Celitech is headquartered in Maryland and maintains a focus on streamlining the manufacturing process to improve patient access to advanced immunotherapies.